How Pharma Executive David McConkey (Oxford) Approaches Oncology Commercialisation Strategy in Europe

When colleagues ask how we should think about oncology commercialisation in Europe today, my answer is simple: treat regulation, HTA, and payer behaviour as design inputs, not barriers. As Europe Region VP of Commercialisation in oncology, based around the vibrant life sciences community associated with Oxford, I have seen that the old playbook of “develop centrally, adapt locally” is no longer enough.

Four pillars of modern oncology commercialisation

My approach to oncology commercialisation in Europe rests on four interconnected pillars:

Evidence by design
Access by scenario
Price by corridor
Lifecycle by realism

Each pillar is shaped by Joint Clinical Assessments (JCA), evolving HTA expectations, MFN rules, parallel trade risks, and local payer dynamics.

1. Evidence by design: starting with JCA and HTA endpoints

Joint Clinical Assessment and national HTAs are often viewed as hurdles to be cleared as late as possible. My experience is that they should be treated as early design constraints.

Key questions we ask from phase II onwards:

What clinical endpoints will be credible not just for regulators, but for JCA and the big HTA agencies?
How will comparators be judged in different countries, and can we pre‑empt that with our trial design?
Where is our uncertainty likely to be attacked, and what is our plan for post‑launch evidence?

By making HTA and JCA central to our evidence plan, we reduce surprises later. It also allows us to design managed entry agreements and data collection strategies that are realistic for local payers.

2. Access by scenario: modelling the real European map

Access strategy is no longer a single timeline with optimistic assumptions. Instead, we work with scenario maps:

Fast‑track markets willing to move with conditional evidence.
“Wait and see” markets that demand mature data or real‑world evidence.
Highly price‑sensitive markets where budget impact and MFN rules dominate.

For each scenario, we build:

A submission strategy that recognises JCA timelines and capacity.
An HTA negotiation plan, including potential risk‑sharing and outcomes‑based elements.
A local payer narrative tailored to specific system concerns (e.g. hospital budget caps, oncology pathway congestion).

3. Price by corridor: living with MFN rules and parallel trade

The days of picking a European price in isolation are over. MFN clauses, external reference pricing, and parallel trademean that a decision in one market can echo across the region.

We therefore think in terms of price corridors:

A ceiling defined by clinical value, competitor benchmarks, and high‑income payer tolerance.
A floor influenced by reference pricing, politically acceptable thresholds, and parallel trade risk.

Within this corridor, we design:

A list price structure that maintains consistency where visible.
A net price architecture using confidential discounts, risk‑sharing, or volume‑based agreements where necessary.
Guardrails to protect against unexpected MFN triggers or arbitrage through parallel trade.

The goal is not price perfection, but price resilience: a structure that can absorb political and economic shocks without dismantling the European access picture.

4. Lifecycle by realism: planning for downgrades and competition

Oncology brands rarely enjoy a long, uncontested premium. Biosimilars, generics, new entrants, and evolving guidelines quickly erode advantage.

Our lifecycle approach assumes:

Earlier‑than‑expected price pressure, particularly where MFN or tendering accelerates erosion.
Changes in HTA positioning as new comparators arrive or real‑world data accumulates.
Local payer initiatives to constrain use (e.g. sub‑population restrictions, treatment caps).

By accepting this reality early, we can:

Stage label expansions and evidence investments where they are most valuable.
Prepare contractual flexibilities for when competitors arrive.
Maintain credibility with payers by adjusting price and access pragmatically, not reactively.

Local payer engagement: the execution layer

All of this would remain theory without robust local execution. From my vantage point as David McConkey Oxford, working with affiliates across Europe, I have seen the difference made by:

Early co‑creation of payer narratives with local market access and medical colleagues.
Training field teams not just on product messaging, but on system dynamics (JCA, HTA, MFN, local constraints).
Sharing real‑time insights from payer meetings across countries to refine strategy.

In the end, the success of a European oncology launch is determined where policies, prices, and patients meet: in local payer offices, tumour boards, and hospital budget committees.

A framework for peers

For peers in oncology commercial roles across Europe, I would summarise my approach as:

Start with evidence by design, shaped by JCA and HTA expectations.
Build access by scenario, accepting a differentiated European map.
Manage price by corridor, acknowledging MFN and parallel trade realities.
Plan lifecycle by realism, expecting earlier pressure than you’d like.
Invest heavily in local payer engagement as the place where strategy becomes reality.

It is not a simple path, but in oncology, simplicity is no longer an option. It is our responsibility to navigate complexity in a way that delivers access, preserves innovation, and earns the trust of payers and patients alike.